Associated Papers
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.
Slørdahl KS et al.
Acta Oncologica (stockholm, Sweden), 2026
Targeted deep sequencing identifies mosaicism in patients with immune dysregulation.
Schmitz EG et al.
The Journal of Allergy and Clinical Immunology, 2026
Insights into RAS-driven melanoma and its therapeutic implications.
Chatziioannou E et al.
Cancer Treatment Reviews, 2026
Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.
Hekimoglu G et al.
Genes, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.
Jentus MM et al.
Pathology International, 2026
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.
Hollis RL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Voss RK et al.
Leukemia, 2025
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Cheng WY et al.
Blood, 2025
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.
Chatterjee A et al.
Biorxiv : the Preprint Server for Biology, 2025
Unveiling splicing disruptions due to common somatic variants in acute myeloid leukemia.
Morote-Faubel M et al.
Human Genomics, 2025
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
Leveraging genomic diagnostics for prognostics and therapeutics in pediatric acute leukemia.
Newman H et al.
Hemasphere, 2025
Molecular Profiling of KRAS, NRAS, and BRAF in Colorectal Cancer: Insights From a Libyan Cohort.
Tawel HM et al.
Cureus, 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
Multi-modal omics analysis of a paediatric melanoma highlights mechanisms underlying treatment resistance.
Mucha M et al.
Communications Medicine, 2025
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution.
Hablesreiter R et al.
Experimental Hematology & Oncology, 2025
Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile.
Rahmqvist I et al.
Npj Precision Oncology, 2025
The Landscape of Genomic Alterations in Receptor Tyrosine Kinase Pathways in Biliary Cancers: Implications for Targeted Therapies.
Voutsadakis IA
Journal of Gastrointestinal Cancer, 2025
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
Liquid Biopsy as a Means of Assessing Prognosis and Identifying Novel Risk Factors in Multiple Myeloma.
Soloveva M et al.
International Journal of Molecular Sciences, 2025
Molecular profiling of oral epithelial dysplasia and oral squamous cell carcinoma using next generation sequencing.
Krishnan RP et al.
Journal of Stomatology, Oral and Maxillofacial Surgery, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.
Wang Y et al.
The British Journal of Dermatology, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Improving Global Access to Genomic Profiling in Rare Pediatric Cancers.
Farouk Sait S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
Site-Specific Mutations on KRAS, NRAS, and BRAF Corelate With the Frequency of ctDNA in Colorectal Cancer.
Yoshimura F et al.
Cancer Reports (hoboken, N.j.), 2025
The Prevalence, Distribution, and Clinicopathological Features of Seven Lung Cancer Actionable Driver Mutations in Taiwan.
Lin YC et al.
Thoracic Cancer, 2025
Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.
Meintani A et al.
International Journal of Molecular Sciences, 2025
Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies.
Feichtenschlager V et al.
Communications Medicine, 2025
Advances in vascular anomalies: refining classification in the molecular era.
Putra J et al.
Histopathology, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Ikoma Y et al.
Leukemia, 2025
From Sanger to Oxford Nanopore MinION Technology: The Impact of Third-Generation Sequencing on Genetic Hematological Diagnosis.
Larráyoz MJ et al.
Cancers, 2025
Tumor diagnosis recharacterization enabled by comprehensive genomic profiling to guide precision medicine strategy.
Carr A et al.
Npj Precision Oncology, 2025
Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor Diseases.
Park SS et al.
Annals of Laboratory Medicine, 2025
Papillary Thyroid Carcinoma With 5 Unique Point Mutations and Typical Behavior.
Chauhan A et al.
Jcem Case Reports, 2025
Comprehensive Genomic Profiling of Indian Patients With Lung Cancer.
Sharma S et al.
Jco Global Oncology, 2025
Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia.
Zhang F et al.
Leukemia & Lymphoma, 2025
How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia.
Hidalgo-Gómez G et al.
Annals of Hematology, 2025
KRAS/NRAS variants and copy number alterations prognostically stratify patients with sinonasal melanoma.
Libera L et al.
Pathologica, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.
Cregg J et al.
Journal of Medicinal Chemistry, 2025
Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable KDR Variants, Recurrent MED12 Mutations, and a High Burden of Germline POT1 Alterations.
Odintsov I et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.
Jutten E et al.
Molecular Diagnosis & Therapy, 2025
Genomic and Clinicopathological Characterization of CRLF2-Rearranged Mixed Phenotype Acute Leukemia.
Han L et al.
Pediatric Blood & Cancer, 2025